The utility and limitations of 18F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: Single institution experience and literature review

Chan Y. Cheah; Michael S. Hofman; John F. Seymour; David S. Ritchie; Michael Dickinson; Andrew Wirth; H. Miles Prince; Max Wolf; Elchanan H. Januszcewicz; Dennis A. Carney; Kirsten E. Herbert; Simon J. Harrison; Kate L. Burbury; Constantine S. Tam

doi:10.3109/10428194.2014.910656

The utility and limitations of ¹⁸F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: Single institution experience and literature review

Chan Y. Cheah, Michael S. Hofman, John F. Seymour, David S. Ritchie, Michael Dickinson, Andrew Wirth, H. Miles Prince, Max Wolf, Elchanan H. Januszcewicz, Dennis A. Carney, Kirsten E. Herbert, Simon J. Harrison, Kate L. Burbury, Constantine S. Tam

Research output: Contribution to journal › Review article › peer-review

15 Citations (Scopus)

Abstract

There are limited data regarding the role of ¹⁸F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET-CT) scanning in primary mediastinal B-cell lymphoma (PMBL). We analyzed 28 patients with PMBL treated with chemotherapy, of whom 25 (89%) also received rituximab and 17 (61%) radiotherapy. PET-CT scans were interpreted using visual analysis and a 5-point scale. After a median follow-up of 2.6 years, four patients relapsed and two died. The 2-year progression-free survival and overall survival were 86% and 94%. PET-CT has excellent negative predictive value (interim, 86-87%; end of treatment, 95%) but limited positive predictive value due to the high frequency of positive scans. Several patients with persistent metabolically active masses underwent biopsies, which showed necrosis but no lymphoma. Thus a negative PET-CT is an excellent predictor of subsequent outcome. However, residual metabolically active masses after treatment should be biopsied to confirm viable lymphoma prior to salvage therapy.

Original language	English
Pages (from-to)	49-56
Number of pages	8
Journal	LEUKEMIA & LYMPHOMA
Volume	56
Issue number	1
DOIs	https://doi.org/10.3109/10428194.2014.910656
Publication status	Published - 1 Jan 2015
Externally published	Yes

Access to Document

10.3109/10428194.2014.910656

Fingerprint

Dive into the research topics of 'The utility and limitations of ¹⁸F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: Single institution experience and literature review'. Together they form a unique fingerprint.

Cite this

Cheah, C. Y., Hofman, M. S., Seymour, J. F., Ritchie, D. S., Dickinson, M., Wirth, A., Prince, H. M., Wolf, M., Januszcewicz, E. H., Carney, D. A., Herbert, K. E., Harrison, S. J., Burbury, K. L., & Tam, C. S. (2015). The utility and limitations of ¹⁸F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: Single institution experience and literature review. LEUKEMIA & LYMPHOMA, 56(1), 49-56. https://doi.org/10.3109/10428194.2014.910656

Cheah, Chan Y. ; Hofman, Michael S. ; Seymour, John F. ; Ritchie, David S. ; Dickinson, Michael ; Wirth, Andrew ; Prince, H. Miles ; Wolf, Max ; Januszcewicz, Elchanan H. ; Carney, Dennis A. ; Herbert, Kirsten E. ; Harrison, Simon J. ; Burbury, Kate L. ; Tam, Constantine S. / The utility and limitations of ¹⁸F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma : Single institution experience and literature review. In: LEUKEMIA & LYMPHOMA. 2015 ; Vol. 56, No. 1. pp. 49-56.

@article{233a7dadb3d34ea392539fa5fe9d79d9,

title = "The utility and limitations of 18F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: Single institution experience and literature review",

abstract = "There are limited data regarding the role of 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET-CT) scanning in primary mediastinal B-cell lymphoma (PMBL). We analyzed 28 patients with PMBL treated with chemotherapy, of whom 25 (89%) also received rituximab and 17 (61%) radiotherapy. PET-CT scans were interpreted using visual analysis and a 5-point scale. After a median follow-up of 2.6 years, four patients relapsed and two died. The 2-year progression-free survival and overall survival were 86% and 94%. PET-CT has excellent negative predictive value (interim, 86-87%; end of treatment, 95%) but limited positive predictive value due to the high frequency of positive scans. Several patients with persistent metabolically active masses underwent biopsies, which showed necrosis but no lymphoma. Thus a negative PET-CT is an excellent predictor of subsequent outcome. However, residual metabolically active masses after treatment should be biopsied to confirm viable lymphoma prior to salvage therapy.",

keywords = "Interim PET-CT, Non-Hodgkin lymphoma, PET-CT, Primary mediastinal B-cell lymphoma, Prognostic factors, Risk adapted therapy",

author = "Cheah, {Chan Y.} and Hofman, {Michael S.} and Seymour, {John F.} and Ritchie, {David S.} and Michael Dickinson and Andrew Wirth and Prince, {H. Miles} and Max Wolf and Januszcewicz, {Elchanan H.} and Carney, {Dennis A.} and Herbert, {Kirsten E.} and Harrison, {Simon J.} and Burbury, {Kate L.} and Tam, {Constantine S.}",

year = "2015",

month = jan,

day = "1",

doi = "10.3109/10428194.2014.910656",

language = "English",

volume = "56",

pages = "49--56",

journal = "LEUKEMIA & LYMPHOMA",

issn = "1026-8022",

publisher = "Informa Healthcare USA",

number = "1",

}

Cheah, CY, Hofman, MS, Seymour, JF, Ritchie, DS, Dickinson, M, Wirth, A, Prince, HM, Wolf, M, Januszcewicz, EH, Carney, DA, Herbert, KE, Harrison, SJ, Burbury, KL & Tam, CS 2015, 'The utility and limitations of ¹⁸F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: Single institution experience and literature review', LEUKEMIA & LYMPHOMA, vol. 56, no. 1, pp. 49-56. https://doi.org/10.3109/10428194.2014.910656

The utility and limitations of ¹⁸F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma : Single institution experience and literature review. / Cheah, Chan Y.; Hofman, Michael S.; Seymour, John F.; Ritchie, David S.; Dickinson, Michael; Wirth, Andrew; Prince, H. Miles; Wolf, Max; Januszcewicz, Elchanan H.; Carney, Dennis A.; Herbert, Kirsten E.; Harrison, Simon J.; Burbury, Kate L.; Tam, Constantine S.

In: LEUKEMIA & LYMPHOMA, Vol. 56, No. 1, 01.01.2015, p. 49-56.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - The utility and limitations of 18F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma

T2 - Single institution experience and literature review

AU - Cheah, Chan Y.

AU - Hofman, Michael S.

AU - Seymour, John F.

AU - Ritchie, David S.

AU - Dickinson, Michael

AU - Wirth, Andrew

AU - Prince, H. Miles

AU - Wolf, Max

AU - Januszcewicz, Elchanan H.

AU - Carney, Dennis A.

AU - Herbert, Kirsten E.

AU - Harrison, Simon J.

AU - Burbury, Kate L.

AU - Tam, Constantine S.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - There are limited data regarding the role of 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET-CT) scanning in primary mediastinal B-cell lymphoma (PMBL). We analyzed 28 patients with PMBL treated with chemotherapy, of whom 25 (89%) also received rituximab and 17 (61%) radiotherapy. PET-CT scans were interpreted using visual analysis and a 5-point scale. After a median follow-up of 2.6 years, four patients relapsed and two died. The 2-year progression-free survival and overall survival were 86% and 94%. PET-CT has excellent negative predictive value (interim, 86-87%; end of treatment, 95%) but limited positive predictive value due to the high frequency of positive scans. Several patients with persistent metabolically active masses underwent biopsies, which showed necrosis but no lymphoma. Thus a negative PET-CT is an excellent predictor of subsequent outcome. However, residual metabolically active masses after treatment should be biopsied to confirm viable lymphoma prior to salvage therapy.

AB - There are limited data regarding the role of 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET-CT) scanning in primary mediastinal B-cell lymphoma (PMBL). We analyzed 28 patients with PMBL treated with chemotherapy, of whom 25 (89%) also received rituximab and 17 (61%) radiotherapy. PET-CT scans were interpreted using visual analysis and a 5-point scale. After a median follow-up of 2.6 years, four patients relapsed and two died. The 2-year progression-free survival and overall survival were 86% and 94%. PET-CT has excellent negative predictive value (interim, 86-87%; end of treatment, 95%) but limited positive predictive value due to the high frequency of positive scans. Several patients with persistent metabolically active masses underwent biopsies, which showed necrosis but no lymphoma. Thus a negative PET-CT is an excellent predictor of subsequent outcome. However, residual metabolically active masses after treatment should be biopsied to confirm viable lymphoma prior to salvage therapy.

KW - Interim PET-CT

KW - Non-Hodgkin lymphoma

KW - PET-CT

KW - Primary mediastinal B-cell lymphoma

KW - Prognostic factors

KW - Risk adapted therapy

UR - http://www.scopus.com/inward/record.url?scp=84922381402&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.910656

DO - 10.3109/10428194.2014.910656

M3 - Review article

C2 - 24724780

AN - SCOPUS:84922381402

VL - 56

SP - 49

EP - 56

JO - LEUKEMIA & LYMPHOMA

JF - LEUKEMIA & LYMPHOMA

SN - 1026-8022

IS - 1

ER -